PARATEK PHARMACEUTICALS INC (PRTK)
US6993743029 - Common Stock
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and...
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the...
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Follows the recommendation from ISS to vote FOR the transaction...
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings").
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, NEWR, PRTK
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
/PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc....
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTK
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRTK, PTEN, NEX, BG
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
/PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc....
NexPoint sends demand letter to Paratek Pharma (NASDAQ:PRTK)
Paratek Pharmaceuticals' (PRTK) investor NexPoint Asset Management has sent a demand letter to the clinical-stage biotech. Read more here.
NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital
/PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) (the...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, PTEN, NEX, PRTK
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in...
IMPORTANT ALERT: Halper Sadeh LLC Investigates WMC, SGTX, PRTK
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Paratek antibiotic Nuzyra to receive EU orphan drug status (PRTK)
Paratek Pharmaceuticals (PRTK) said that an EMA advisory committee has issued a positive opinion on its drug Nuzyra receiving orphan drug status in the EU for a rare lung disease.
Paratek investor NexPoint warns it may vote against takeover deal (PRTK)
Paratek Pharmaceuticals (PRTK) investor NexPoint Asset Management said that it may vote against the biotech company's planned takeover by Gurnet Point Capital. Read more here.
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused...
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates QUOT, PRTK, TESS, HMPT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, PRTK, KDNY
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
PRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP investigates whether Paratek Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Gurnet Point Capital and Novo Holdings
/PRNewswire/ -- Ademi LLP is investigating Paratek (Nasdaq: PRTK) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Paratek to be taken private in deal worth up to $462M (PRTK)
Antibiotic developer Paratek Pharmaceuticals (PRTK) has agreed to be taken private by Gurnet Point Capital and Novo Holdings via a deal worth up to $462M. Read more here.
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including...
7 Growth Stocks That Are Too Cheap to Ignore Right Now
Although riskier than usual, these cheap growth stocks to buy now may help liven up your portfolio during these strange times.
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and...
Monday Sector Laggards: Drugs, Application Software Stocks
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the...